The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
Abstract
OBJECTIVE: To evaluate the efficacy and safety of 30, 50, and 70 mg/day lisdexamfetamine dimesylate compared with placebo in adults with attention-deficit/hyperactivity disorder (ADHD). METHOD: Following a 7- to 28-day washout, 420 adults aged 18 to 55 years with moderate to severe ADHD (DSM-IV-TR criteria) were treated with 30, 50, or 70 mg/day lisdexamfetamine or placebo, respectively, for 4 weeks (N = 119, 117, 122, and 62, respectively). The 50- and 70- mg/day groups underwent forced-dose titration. The primary efficacy measure was the clinician-determined ADHD Rating Scale (ADHD-RS) total score. The study was conducted from May 2006 to November 2006. RESULTS: Treatment groups were well matched at baseline, including in ADHD-RS scores. At endpoint, changes in ADHD-RS scores were significantly greater for each lisdexamfetamine dose than for placebo (placebo = -8.2, 30 mg/day lisdexamfetamine = -16.2, 50 mg/day lisdexamfetamine = -17.4, 70 mg/day lisdexamfetamine = -18.6; all p < .0001 vs. placebo), with no differences between doses. Significant differences relative to placebo were observed in each lisdexamfetamine group, beginning at week 1 and for each week throughout. The percentage of subjects who improved (Clinical Global Impressions-Improvement scale rating < or = 2) was significantly greater for each lisdexamfetamine dose than for placebo at each week and at endpoint (placebo = 29%, 30 mg/day lisdexamfetamine = 57%, 50 mg/day lisdexamfetamine = 62%, 70 mg/day lisdexamfetamine = 61%; all p < .01). Adverse events were generally mild and included dry mouth, decreased appetite, and insomnia. CONCLUSION: All 3 lisdexamfetamine doses were significantly more effective than placebo in the treatment of adults with ADHD, with improvements noted within 1 week. Lisdexamfetamine was generally well tolerated by these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Discontinuations due to TEAEs with LDX in these studies (6.3% and 3.9%) are comparable to a published phase 2 study of LDX in BED (McElroy et al, 2015), to other clinical studies of LDX for which LDX is indicated (Adler et al, 2008; Wigal et al, 2010), and to other BED pharmacotherapy trials with other agents (Claudino et al, 2007; McElroy et al, 2003, 2007a, b).”
From Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials (2016) · cites this paper as Adler et al, 2008
In the citing paper
“The safety and tolerability profile of LDX observed regarding overall TEAEs, TEAEs leading to discontinuation, vital signs, and ECGs were consistent with published reports in adults with BED (McElroy et al, 2015) or attention-deficit/hyperactivity disorder (Adler et al, 2008; Wigal et al, 2010).”
From Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials (2016) · cites this paper as Adler et al, 2008
In the citing paper
“Lisdexamfetamine dimesylate is not metabolized by cytochrome P450 enzymes and unlikely to be involved in drug interactions involving CYP enzymes or P-glycoprotein; however, it is contraindicated during or within 2 weeks following the administration of monoamine oxidase inhibitors.”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [21]
In the citing paper
“in placebo-controlled LDX trials in ADHD, participants were considered treatment “responders” if they had a ≥ 30% reduction in ADHD symptoms using a standardized scale [27–29].”
From Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine (2024) · cites this paper as [27]
In the citing paper
“Improvements observed from LDX versus placebo in this trial were comparable to those observed in LDX interventions for adults with ADHD [16,27–29].”
From Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine (2024) · cites this paper as [27]
In the citing paper
“Previously reported abuse liability studies support the reduced abuse potential of LDX administered orally at doses ≤150 mg or intravenously at doses ≤50 mg, compared with d-amphetamine immediate-release 40 mg oral or 20 mg intravenous doses, respectively.21”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [21]
In the citing paper
“An intention-to-treat analysis was applied in two studies.16,18”
From Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD (2014) · cites this paper as [16]
In the citing paper
“Unfortunately, only one study reported remission rates,16 and its pooled remission rate could not be calculated.”
From Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD (2014) · cites this paper as [16]
In the citing paper
“Although some randomized controlled trials (RCTs) of LDX demonstrated its efficacy and tolerability, compared with placebo, in the treatment of adult ADHD,16,18–21 they had a limited sample size.”
From Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD (2014) · cites this paper as [16]
In the citing paper
“The evidence suggests that LDX is an effective, safe, well-tolerated medication for children aged 6 to 12 years through to adulthood, with ADHD.16,17”
From Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD (2014) · cites this paper as [16]
In the citing paper
“Additionally, allocation concealment was reported in two trials18,21 and blinding of outcome assessment was reported in three trials.16,20,21”
From Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD (2014) · cites this paper as [16]
In the citing paper
“Six percent of subjects in the lisdexamfetamine group discontinued the drug owing to side effects, the most common being insomnia. Palpitations, hypertension, and dyspnea were also more common in the treatment group than in the placebo group.”
From Update on optimal use of lisdexamfetamine in the treatment of ADHD (2013) · cites this paper as [27]
In the citing paper
“In a randomized, placebo-controlled trial of 420 adult subjects with ADHD, Adler et al27 found statistically significant improvements in ADHD-RS-IV and CGI scores for all doses of lisdexamfetamine (30–50 mg) compared with placebo. These improvements were evident from the first week.”
From Update on optimal use of lisdexamfetamine in the treatment of ADHD (2013) · cites this paper as [27]
In the citing paper
“The common AEs in the current study, including decreased appetite, dry mouth, headache, and insomnia, are consistently seen in studies of long-acting stimulant medications administered to adults [12,18,35,36].”
In the citing paper
“LDX has demonstrated efficacy in reducing core ADHD symptoms in a randomized, controlled trial in adults [26], using the ADHD Rating Scale IV (ADHD-RS-IV) [27,28]”
In the citing paper
“The overall safety and tolerability findings observed in these studies are consistent with previously published studies of LDX augmentation for MDD with other clinical studies of LDX for which LDX is approved for use (Adler et al., 2008;Madhoo et al., 2014;McElroy et al., 2016;Trivedi et al., 2013Wigal et al., 2010).”
In the citing paper
“Multiple randomized, double-blind, placebo-controlled trials have shown LDX to be an effective treatment for children, adolescents and adults with ADHD, with a tolerability and safety profile consistent with the known effects of psychostimulant therapy [9–15].”
In the citing paper
“These results support previous placebo-controlled trials of LDX, which have demonstrated a robust treatment response in a range of patient groups [9, 11–13].”
In the citing paper
“Both therapies displayed safety profiles consistent with findings from previous studies [9, 11–13, 28–30].”
In the citing paper
“The most frequently reported TEAEs in the LDX treatment group (decreased appetite, decreased weight, headache, nausea and insomnia) and in patients receiving ATX (headache, nausea, somnolence, decreased appetite and fatigue) are consistent with findings from previous studies [9, 11–13, 28–30].”
Citations
Cites
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
(1976) · Medical Entomology and Zoology · Cited by 8,899
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
Self-citationKessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886
Self-citation(1998) · Cited by 2,026
BARKLEY, R. A., FISCHER, M., EDELBROCK, C. S., & SMALLISH, L. (1990) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199007000-00007 · Cited by 1,507
Guy, W. L. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,441
General hospital psychiatry: the Italian experience.
Faraone, S. V., Sergeant, J. A., Gillberg, C., & Biederman, J. (2003) · Europe PMC (PubMed Central) · Cited by 1,277
Self-citationBarkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2002) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.111.2.279 · Cited by 1,199
Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Cited by
Sorted by citations
Updated European Consensus Statement on diagnosis and treatment of adult ADHD
Kooij, J. J. S., Bijlenga, D., Salerno, L., Jaeschke, R., Bitter, I., Balázs, J., Thome, J., Dom, G., Kasper, S., Nunes Filipe, C., et al. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2018.11.001 · Cited by 686
Amphetamine, past and present – a pharmacological and clinical perspective
Heal, D. J., Smith, S. L., Gosden, J., & Nutt, D. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113482532 · Cited by 653
Faraone, S. V., & Glatt, S. J. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04902pur · Cited by 387
Associations of sleep disturbance with ADHD: implications for treatment
Hvolby, A. (2015) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-014-0151-0 · Cited by 339
McElroy, S. L., Hudson, J. I., Mitchell, J. E., Wilfley, D., Ferreira-Cornwell, M. C., Gao, J., Wang, J., Whitaker, T., Jonas, J., & Gasior, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2162 · Cited by 322
Chang, Z., Lichtenstein, P., D’Onofrio, B. M., Sjölander, A., & Larsson, H. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.4174 · Cited by 293
Bolea-Alamañac, B., Nutt, D. J., Adamou, M., Asherson, P., Bazire, S., Coghill, D., Heal, D., Müller, U., Nash, J., Santosh, P., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113519509 · Cited by 287
McElroy, S. L., Hudson, J., Ferreira-Cornwell, M. C., Radewonuk, J., Whitaker, T., & Gasior, M. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.275 · Cited by 254
Adler, L. A., Liebowitz, M., Kronenberger, W., Qiao, M., Rubin, R., Hollandbeck, M., Deldar, A., Schuh, K., & Durell, T. (2009) · Depression and Anxiety · doi:10.1002/da.20549 · Cited by 176
Self-citationDistinguishing comorbidity and successful management of adult ADHD
Kooij, J. J. S., Huss, M., Asherson, P., Akehurst, R., Beusterien, K., French, A., Sasané, R., & Hodgkins, P. (2012) · Journal of Attention Disorders · doi:10.1177/1087054711435361 · Cited by 172
Attention deficit hyperactivity disorder in adults
Rösler, M., Casas, M., Konofal, É., & Buitelaar, J. K. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.483249 · Cited by 151
Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis
Mészáros, Á., Czobor, P., Bálint, S., Komlósi, S., Simon, V., & Bitter, I. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990198 · Cited by 138
Wigal, T., Brams, M., Gasior, M., Gao, J., Squires, L., Giblin, J., & 316 Study Group (2010) · Behavioral and Brain Functions · doi:10.1186/1744-9081-6-34 · Cited by 136
“Common AEs with LDX in this study included decreased appetite, dry mouth, and insomnia [ 18 ].”
BackgroundResultInfluentialBond, D. J., Hadjipavlou, G., Lam, R. W., McIntyre, R. S., Beaulieu, S., Schaffer, A., & Weiss, M. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400104 · Cited by 133
Mick, E. O., McManus, D. D., & Goldberg, R. J. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.06.011 · Cited by 136
Coghill, D., Banaschewski, T., Lecendreux, M., Soutullo, C., Johnson, M., Zuddas, A., Anderson, C., Civil, R., Higgins, N., Lyne, A., et al. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.11.012 · Cited by 123
Findling, R. L., Childress, A. C., Cutler, A. J., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Squires, L. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.01.007 · Cited by 120
An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults
Wilens, T. E., Morrison, N. R., & Prince, J. B. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.137 · Cited by 117
Thurstone, C., Riggs, P. D., Salomonsen-Sautel, S., & Mikulich-Gilbertson, S. K. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.02.013 · Cited by 96
Weisler, R., Young, J., Mattingly, G., Gao, J., Squires, L., Adler, L., & 304 Study Group (2009) · CNS Spectrums · doi:10.1017/s1092852900024056 · Cited by 94
Self-citationZalsman, G., & Shilton, T. (2016) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2016.1149197 · Cited by 103
A Systematic Review of the Safety of Lisdexamfetamine Dimesylate
Coghill, D. R., Caballero, B., Sorooshian, S., & Civil, R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0166-2 · Cited by 89
Dittmann, R. W., Cardo, E., Nagy, P., Anderson, C. S., Bloomfield, R., Caballero, B., Higgins, N., Hodgkins, P., Lyne, A., Civil, R., et al. (2013) · CNS Drugs · doi:10.1007/s40263-013-0104-8 · Cited by 88
DuPaul, G. J., Weyandt, L. L., Rossi, J. S., Vilardo, B. A., O’Dell, S. M., Carson, K. M., Verdi, G., & Swentosky, A. (2012) · Journal of Attention Disorders · doi:10.1177/1087054711427299 · Cited by 86
“…rates for placebo and individual dosages are similar to those found previously for adolescents (Findling et al., 2011) and adults with ADHD (Adler et al., 2008), and the overall rate of response to any LDX dosage is very similar to that found for children with ADHD (Findling, Ginsberg,…”
BackgroundResultInfluentialChristensen, L., Sasané, R., Hodgkins, P., Harley, C., & Tetali, S. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003673617 · Cited by 86
Weyandt, L. L., Oster, D. R., Marraccini, M. E., Guðmundsdóttir, B. G., Munro, B. A., Zavras, B. M., & Kuhar, B. G. (2014) · Psychology Research and Behavior Management · doi:10.2147/prbm.s47013 · Cited by 95
Elliott, J., Johnston, A., Husereau, D., Kelly, S., Eagles, C., Charach, A., Hsieh, S., Bai, Z., Hossain, A., Skidmore, B., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240584 · Cited by 103
The Health Effect of Psychostimulants: A Literature Review
Favrod-Coune, T., & Broers, B. (2010) · Pharmaceuticals · doi:10.3390/ph3072333 · Cited by 84
McElroy, S. L., Mitchell, J. E., Wilfley, D. E., Gasior, M., Ferreira‐Cornwell, M. C., McKay, M., Wang, J., Whitaker, T., & Hudson, J. I. (2015) · European Eating Disorders Review · doi:10.1002/erv.2418 · Cited by 82
Ermer, J., Homolka, R., Martin, P., Buckwalter, M., Purkayastha, J., & Roesch, B. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009357346 · Cited by 72
Boellner, S. W., Stark, J. G., Krishnan, S., & Zhang, Y. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.02.011 · Cited by 72
Self-citationLisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy
Ermer, J. C., Pennick, M., & Frick, G. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-015-0354-y · Cited by 67
ADHD in old age: a review of the literature and proposal for assessment and treatment
Kooij, J. J. S., Michielsen, M., Kruithof, H. C., & Bijlenga, D. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1204914 · Cited by 69
Banaschewski, T., Soutullo, C. A., Lecendreux, M., Johnson, M., Zuddas, A., Hodgkins, P., Adeyi, B. A., Squires, L. A., & Coghill, D. (2013) · CNS Drugs · doi:10.1007/s40263-013-0095-5 · Cited by 63
Santosh, P. J., Sattar, S., & Canagaratnam, M. (2011) · CNS Drugs · doi:10.2165/11593070-000000000-00000 · Cited by 62
Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults
Castells, X., Blanco-Silvente, L., & Cunill, R. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007813.pub3 · Cited by 209
Biederman, J., Fried, R., Hammerness, P., Surman, C., Mehler, B., Petty, C. R., Faraone, S. V., Miller, C., Bourgeois, M., Meller, B., et al. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.01.007 · Cited by 60
Self-citationCoghill, D., Banaschewski, T., Lecendreux, M., Johnson, M., Zuddas, A., Anderson, C. S., Civil, R. H., Dauphin, M., Higgins, N., Lyne, A., et al. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.01.017 · Cited by 58
Lisdexamfetamine: A Review in Binge Eating Disorder
Heo, Y., & Duggan, S. T. (2017) · CNS Drugs · doi:10.1007/s40263-017-0477-1 · Cited by 56
Burton, B. K., Grant, M., Feigenbaum, A., Singh, R. H., Hendren, R. L., Siriwardena, K., Phillips, J., Sanchez‐Valle, A., Waisbren, S. E., Gillis, J., et al. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.11.011 · Cited by 55
Geissler, J. M., & Lesch, K. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.136 · Cited by 57
Adler, L. A., Adams, J., Madera‐McDonough, J., Kohegyi, E., Hobart, M., Chang, D., Angelicola, M., McQuade, R. D., & Liebowitz, M. R. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001575 · Cited by 52
Self-citationApostol, G., Abi‐Saab, W., Kratochvil, C. J., Adler, L. A., Robieson, W., Gault, L. M., Pritchett, Y., Feifel, D., Collins, M. A., & Saltarelli, M. D. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2393-2 · Cited by 53
Self-citationPharmacotherapy of ADHD in Adults
Wilens, T. E. (2008) · CNS Spectrums · doi:10.1017/s1092852900002960 · Cited by 50
Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults
Castells, X., Ramos-Quiroga, J. A., Bosch, R., Nogueira, M., & Casas, M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007813.pub2 · Cited by 80
Do stimulants improve functioning in adults with ADHD?
Surman, C. B. H., Hammerness, P. G., Pion, K., & Faraone, S. V. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.02.010 · Cited by 47
Lasser, R. A., Dirks, B., Nasrallah, H. A., Kirsch, C., Gao, J., Pucci, M. L., Knesevich, M. A., & Lindenmayer, J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.111 · Cited by 46
Stuhec, M., Lukić, P., & Locatelli, I. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028018795703 · Cited by 46
Goodman, D. W., & Thase, M. E. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2049 · Cited by 47
Self-citationAdler, L. A., Dirks, B., Deas, P., Raychaudhuri, A., Dauphin, M., Saylor, K., & Weisler, R. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-253 · Cited by 45
Self-citationThe Pharmacology and Clinical Outcomes of Amphetamines to Treat ADHD
Hodgkins, P., Shaw, M., McCarthy, S., & Sallee, F. R. (2012) · CNS Drugs · doi:10.2165/11599630-000000000-00000 · Cited by 45
Mooney, M. E., Herin, D. V., Specker, S. M., Babb, D. A., LEVIN, F. R., & Grabowski, J. G. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.05.042 · Cited by 44
Coghill, D. R., Banaschewski, T., Nagy, P., Otero, I. H., Soutullo, C., Yan, B., Caballero, B., & Zuddas, A. (2017) · CNS Drugs · doi:10.1007/s40263-017-0443-y · Cited by 45
López, F. A., & Leroux, J. R. (2013) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-013-0106-x · Cited by 43
Banaschewski, T., Johnson, M., Lecendreux, M., Zuddas, A., Adeyi, B., Hodgkins, P., Squires, L. A., & Coghill, D. R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0193-z · Cited by 41
Effects of Lisdexamfetamine Dimesylate Treatment for ADHD on Growth
Faraone, S. V., Spencer, T. J., Kollins, S. H., & Glatt, S. J. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-201001000-00006 · Cited by 39
Self-citationFindling, R. L., Cutler, A. J., Saylor, K., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Childress, A. C. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0088 · Cited by 40
Effect of Lisdexamfetamine Dimesylate on Sleep in Children With ADHD
Giblin, J. M., & Strobel, A. L. (2011) · Journal of Attention Disorders · doi:10.1177/1087054710371195 · Cited by 38
Tramontana, M. G., Cowan, R. L., Zald, D. H., Prokop, J. W., & Guillamondegui, O. D. (2014) · Brain Injury · doi:10.3109/02699052.2014.930179 · Cited by 38
Lisdexamfetamine: A Review in ADHD in Adults
Frampton, J. E. (2016) · CNS Drugs · doi:10.1007/s40263-016-0327-6 · Cited by 37
Goodman, D. W. (2010) · PubMed Central · Cited by 36
Self-citationPharmacological treatment of adult ADHD in Europe
Retz, W., Retz‐Junginger, P., Thome, J., & Rösler, M. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.603229 · Cited by 37
Adler, L. A., Goodman, D., Weisler, R. H., Hamdani, M., & Roth, T. G. (2009) · Behavioral and Brain Functions · doi:10.1186/1744-9081-5-34 · Cited by 36
Self-citationErmer, J. C., Dennis, K., Haffey, M. B., Doll, W. J., Sandefer, E. P., Buckwalter, M., Page, R. C., Diehl, B., & Martin, P. T. (2011) · Clinical Drug Investigation · doi:10.2165/11588190-000000000-00000 · Cited by 35
Epilepsy and Attention Deficit Hyperactivity Disorder: Connection, Chance, and Challenges
Fan, H., Chiang, K.-L., Chang, K., Chen, C., & Tsai, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065270 · Cited by 39
Haffey, M. B., Buckwalter, M., Zhang, P., Homolka, R., Martin, P., Lasseter, K. C., & Ermer, J. C. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2048 · Cited by 34
Toward Quality Care in ADHD: Defining the Goals of Treatment
Rostain, A., Jensen, P. S., Connor, D. F., Miesle, L. M., & Faraone, S. V. (2015) · Journal of Attention Disorders · doi:10.1177/1087054712473835 · Cited by 33
Coghill, D. R., Banaschewski, T., Lecendreux, M., Zuddas, A., Dittmann, R. W., Otero, I. H., Civil, R., Bloomfield, R., & Squires, L. A. (2014) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-013-0421-y · Cited by 33
Faraone, S. V. (2010) · Journal of Attention Disorders · doi:10.1177/1087054710379738 · Cited by 32
Mattingly, G. W., Weisler, R. H., Young, J. L., Adeyi, B. A., Dirks, B., Babcock, T., Lasser, R. A., Scheckner, B., & Goodman, D. W. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-39 · Cited by 32
Self-citationWard, K., & Citrome, L. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1420163 · Cited by 32
McIntyre, R. S., Alsuwaidan, M. T., Soczynska, J. K., Szpindel, I., Bilkey, T. S., Almagor, D., Woldeyohannes, H. O., Powell, A. M., Cha, D. S., Gallaugher, L. A., et al. (2013) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2325 · Cited by 31
Dittmann, R., Cardo, E., Nagy, P., Anderson, C. S., Adeyi, B. A., Caballero, B., Hodgkins, P., Civil, R. H., & Coghill, D. (2014) · CNS Drugs · doi:10.1007/s40263-014-0188-9 · Cited by 32
Schoeman, R., & Liebenberg, R. (2017) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v23i0.1060 · Cited by 37
Lisdexamfetamine Dimesylate: A New Therapeutic Option for Attention-Deficit Hyperactivity Disorder
Steer, C., Froelich, J., Soutullo, C. A., Johnson, M., & Shaw, M. (2012) · CNS Drugs · doi:10.2165/11634340-000000000-00000 · Cited by 30
Philip, P., Micoulaud‐Franchi, J., Lagarde, E., Taillard, J., Canel, A., Sagaspe, P., & Bioulac, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138004 · Cited by 34
Wigal, T. L., Newcorn, J. H., Handal, N. M., Wigal, S. B., Mulligan, I., Schmith, V. D., & Konofal, É. (2018) · CNS Drugs · doi:10.1007/s40263-018-0503-y · Cited by 30
Brown, T. E., Brams, M., Gao, J., Gasior, M., & Childress, A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.09.2196 · Cited by 29
Frick, G. S., Yan, B. M., & Adler, L. A. (2017) · Journal of Attention Disorders · doi:10.1177/1087054717696771 · Cited by 29
Self-citationCoghill, D., Banaschewski, T., Bliss, C. A., Robertson, B., & Zuddas, A. (2018) · CNS Drugs · doi:10.1007/s40263-017-0487-z · Cited by 32
Adler, L. A., Alperin, S., Leon, T., & Faraone, S. V. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0121 · Cited by 28
Self-citationExploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD
Maneeton, B., Maneeton, N., Suttajit, S., Reungyos, J., Srisurapanont, M., & Martin, S. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s68393 · Cited by 27
“Adler et al 2008 16 Dupaul et al 2012 20 bias should be examined in meta-analysis but was not assessed here due to the small number of included studies.”
Waxmonsky, J. G., Waschbusch, D. A., Babinski, D. E., Humphrey, H. H., Alfonso, A., Crum, K. I., Bernstein, M., Slavec, J., Augustus, J. N., & Pelham, W. E. (2014) · CNS Drugs · doi:10.1007/s40263-014-0165-3 · Cited by 26
Ginsberg, L., Katic, A., Adeyi, B., Dirks, B., Babcock, T., Lasser, R., Scheckner, B., & Adler, L. A. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.567256 · Cited by 26
Self-citationWeisler, R. H., Greenbaum, M., Arnold, V., Yu, M., Yan, B., Jaffee, M., & Robertson, B. (2017) · CNS Drugs · doi:10.1007/s40263-017-0455-7 · Cited by 26
Self-citationLisdexamfetamine Dimesylate: A Prodrug Stimulant for the Treatment of ADHD in Children and Adults
Mattingly, G. W. (2010) · CNS Spectrums · doi:10.1017/s1092852900027541 · Cited by 25
Kollins, S. H., English, J. S., Itchon-Ramos, N., Chrisman, A. K., Dew, R. E., O’Brien, B., & McClernon, F. J. (2012) · Journal of Attention Disorders · doi:10.1177/1087054712440320 · Cited by 25
Self-citationBrown, T. E., Brams, M., Gasior, M., Adeyi, B., Babcock, T., Dirks, B., Scheckner, B., & Wigal, T. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.605441 · Cited by 24
Lisdexamfetamine: A prodrug for the treatment of attention-deficit/hyperactivity disorder
Popovic, B., Bhattacharya, P., & Sivaswamy, L. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080353 · Cited by 24
Pharmacological Management of Narcolepsy and Cataplexy in Pediatric Patients
Lecendreux, M. (2014) · Pediatric Drugs · doi:10.1007/s40272-014-0083-3 · Cited by 24
Bilder, D. A., Arnold, G. L., Dimmock, D., Grant, M., Janzen, D. M., Longo, N., Nguyen-Driver, M. D., Jurecki, E. R., Merilainen, M. J., Amato, G., et al. (2021) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.62574 · Cited by 23
Adler, L. A., Lynch, L. R., Shaw, D. M., Wallace, S. P., Ciranni, M. A., Briggie, A. M., Kulaga, A., O'Donnell, K. E., & Faraone, S. V. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.09.2461 · Cited by 24
Self-citationBiederman, J., Fried, R., Hammerness, P., Surman, C., Mehler, B., Petty, C. R., Faraone, S. V., Miller, C., Bourgeois, M., Meller, B., et al. (2012) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2012.03.005 · Cited by 24
Self-citationSleep as an outcome measure in ADHD randomized controlled trials: A scoping review
McWilliams, S., Zhou, T., Stöckler, S., Elbe, D., & Ipsiroglu, O. (2022) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2022.101613 · Cited by 23
Richards, C., McIntyre, R. S., Weisler, R., Sambunaris, A., Brawman-Mintzer, O., Gao, J., Geibel, B., Dauphin, M., & Madhoo, M. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.07.006 · Cited by 20
Self-citationBiederman, J., Mick, E., Spencer, T., Surman, C., & Faraone, S. V. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00233.x · Cited by 20
Self-citationErmer, J. C., Haffey, M. B., Doll, W. J., Martin, P., Sandefer, E. P., Dennis, K., Corcoran, M., Trespidi, L., & Page, R. C. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040691 · Cited by 22
Update on optimal use of lisdexamfetamine in the treatment of ADHD
Madaan, V., Kolli, V., Bestha, D., & Shah, M. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s34092 · Cited by 19
“Weisler et al 28 recruited 349 patients from the study by Adler et al 27 for a 12-month, follow-up study, which was completed by 191 patients.”
Ermer, J., Richards, Lasseter, K., Adeyi, Corcoran, Martin, P., & Stanton, B. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s38377 · Cited by 19
The safety of extended-release drug formulations for the treatment of ADHD
Childress, A. C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1317344 · Cited by 22
Metadata
- Authors
- Adler, L. A., Goodman, D. W., Kollins, S. H., Weisler, R. H., Krishnan, S., Zhang, Y., & Biederman, J.
- Affiliations
- NYU Langone Health (US)
- Duke University (US)
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-09-30
- Volume
- 69
- Issue
- 9
- Pages
- 1364-1373
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1979206088
- Cited by
- 218
- References
- 28
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 14 · 2023: 5 · 2022: 12 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 10 · 2017: 16 · 2016: 9 · 2015: 9 · 2014: 19 · 2013: 22 · 2012: 14
- FWCI
- 15.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- lisdexamfetamine dimesylate, adult ADHD, ADHD medication, dose comparison, ADHD Rating Scale, adverse events, stimulant efficacy, xerostomia, appetite loss, insomnia, placebo response, washout period
- MeSH terms
- Lisdexamfetamine Dimesylate, Adolescent, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Dextroamphetamine, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Personality Assessment, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
